Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
US Quantum Stocks Surge After $2 Billion Government Investment 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Universal Music Group Rejects Pershing Square Takeover Proposal 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
CVS Health is projecting another year of solid earnings growth, announcing that its expected 2026 profit will surpass both Wall Street forecasts and its own 2025 earnings outlook. The update, shared during the company’s investor day, underscores the steady progress of its ongoing turnaround strategy led by Chief Executive David Joyner.
Joyner emphasized that CVS has delivered on its commitments throughout the year and will now concentrate on improving consumer experiences and rebuilding trust—an area he described as a major challenge in today’s healthcare marketplace. As part of this effort, the company unveiled a new consumer app designed to integrate CVS services and offer new revenue opportunities for partners.
Shares of CVS climbed nearly 5% to $80.17 in morning trading following the announcement, extending a year of strong market performance. The stock has surged more than 70% in 2025 as the company implemented sweeping changes, including cost reductions, exits from underperforming markets, and enhancements to leadership to restore investor confidence.
Chief Financial Officer Brian Newman highlighted the company’s strong finish to 2025, stating that CVS expects “another year of strong earnings growth in 2026.” The company forecast adjusted earnings between $7.00 and $7.20 per share for 2026, slightly above consensus expectations of $7.16 per share.
While CVS anticipates up to $400 billion in revenue next year—short of analysts’ projected $419.26 billion—the company expects growth momentum to be driven by improved margins in its Aetna insurance arm and CVS Caremark pharmacy benefit management business. CVS also reiterated plans to exit the Affordable Care Act insurance market in 2026 due to rising medical costs.
Additionally, CVS raised its 2025 profit guidance to between $6.60 and $6.70 per share, marking its fourth increase this year. Analysts at Leerink Partners noted that CVS’ near-term performance supports a strong long-term recovery story for the healthcare conglomerate.
